NASDAQ:MDNA

Medicenna Therapeutics (MDNA) Stock Forecast, Price & News

$0.59

-0.02 (-3.28%)

(As of 05/31/2023 ET)

Compare

Today's Range: $0.58
▼
$0.60
50-Day Range: $0.52
▼
$0.82
52-Week Range: $0.40
▼
$1.88

Volume: 7,262 shs
Average Volume: 100,681 shs
Market Capitalization: $41.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Medicenna Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 959.1% Upside
$6.25 Price Target
Short Interest: Healthy
0.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.20) to ($0.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

653rd out of 1,006 stocks

Pharmaceutical Preparations Industry

327th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Medicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.25, Medicenna Therapeutics has a forecasted upside of 959.1% from its current price of $0.59.
Amount of Analyst Coverage
Medicenna Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.69% of the float of Medicenna Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Medicenna Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Medicenna Therapeutics has recently increased by 20.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Medicenna Therapeutics does not currently pay a dividend.
Dividend Growth
Medicenna Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDNA.

2.7

News and Social Media Coverage

News Sentiment
Medicenna Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
Search Interest
Only 7 people have searched for MDNA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 19.68% of the stock of Medicenna Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.20) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Medicenna Therapeutics is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medicenna Therapeutics is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Medicenna Therapeutics has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Medicenna Therapeutics (NASDAQ:MDNA) Stock

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

May 18, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp down on Wednesday (MDNA)

May 17, 2023 | americanbankingnews.com

Medicenna Therapeutics Corp. (NASDAQ:MDNA) Short Interest Up 5.8% in April

May 31, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 16, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp down on Monday (MDNA)

May 6, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp flat on Friday (MDNA)

April 29, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp down on Friday (MDNA)

April 27, 2023 | finance.yahoo.com

Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

April 22, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp up on Friday (MDNA)

May 31, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

April 21, 2023 | americanbankingnews.com

Short Interest in Medicenna Therapeutics Corp. (NASDAQ:MDNA) Rises By 9.9%

April 19, 2023 | msn.com

MDNA: Update on ABILITY Trial…

April 19, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

April 18, 2023 | finance.yahoo.com

Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 17, 2023 | finance.yahoo.com

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

March 30, 2023 | finance.yahoo.com

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

March 15, 2023 | finance.yahoo.com

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

February 7, 2023 | finanznachrichten.de

Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

February 7, 2023 | finance.yahoo.com

Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

January 31, 2023 | finance.yahoo.com

Medicenna to Present at the 2023 Guggenheim Oncology Conference

December 10, 2022 | theglobeandmail.com

Medicenna Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (MDNA)

November 16, 2022 | finance.yahoo.com

MDNA: Enrollment Continues in the Fifth Dosing Cohort of the ABILITY Trial…

November 4, 2022 | seekingalpha.com

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q2 2023 Earnings Call Transcript

November 4, 2022 | finanznachrichten.de

Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

November 4, 2022 | finance.yahoo.com

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

October 25, 2022 | finance.yahoo.com

Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022

September 30, 2022 | finance.yahoo.com

Medicenna Extends Period to Exercise Certain Warrants

September 22, 2022 | finance.yahoo.com

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Company Calendar

Last Earnings: 11/12/2021
Today: 5/31/2023
Next Earnings (Estimated): 6/28/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MDNA
CUSIP: N/A
CIK: 1807983
Web: www.medicenna.com
Phone: (416) 648-5555
Fax: 416-572-7501
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.25
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $2.50
Forecasted Upside/Downside: +316.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -60.96%
Return on Assets: -54.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.30 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 69,640,000
Free Float: 46,587,000
Market Cap: $41.78 million
Optionable: Not Optionable
Beta: 1.23

Key Executives

Fahar Merchant
Chairman, President & Chief Executive Officer

Elizabeth Williams
Chief Financial Officer & Secretary

Martin Bexon
Chief Medical Officer

Rosemina Merchant
Director & Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings or view top-rated stocks.
What is Medicenna Therapeutics' stock price forecast for 2023?: 3 Wall Street analysts have issued 1 year target prices for Medicenna Therapeutics' stock. Their MDNA share price forecasts range from $2.50 to $10.00. On average, they anticipate the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price.
View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts.
How have MDNA shares performed in 2023?: Medicenna Therapeutics' stock was trading at $0.4580 at the beginning of 2023. Since then, MDNA stock has increased by 31.0% and is now trading at $0.60.
View the best growth stocks for 2023 here.
When is Medicenna Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 28th 2023.
View our MDNA earnings forecast.
How were Medicenna Therapeutics' earnings last quarter?: Medicenna Therapeutics Corp. (NASDAQ:MDNA) issued its earnings results on Friday, November, 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. During the same period in the previous year, the firm earned ($0.06) EPS.

What is Medicenna Therapeutics' stock symbol?: Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA."
Who are Medicenna Therapeutics' major shareholders?: Medicenna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (1.18%) and Renaissance Technologies LLC (0.22%).
How do I buy shares of Medicenna Therapeutics?: Shares of MDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Medicenna Therapeutics' stock price today?: One share of MDNA stock can currently be purchased for approximately $0.60.
How much money does Medicenna Therapeutics make?: Medicenna Therapeutics (NASDAQ:MDNA) has a market capitalization of $41.78 million. The company earns $-18,010,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.
How can I contact Medicenna Therapeutics?: Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The official website for the company is www.medicenna.com. The company can be reached via phone at (416) 648-5555, via email at ir@medicenna.com, or via fax at 416-572-7501.

This page (NASDAQ:MDNA) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial